To evaluate trends in allografting from unrelated donors, we conducted a study on 196
consecutive myeloma patients transplanted between 2000 and 2009 in Italy. Twenty-eight …

This study compares the probability of disease progression, progression-free survival, and
overall survival between patients undergoing an allogeneic or autologous transplant for …

A total of 228 patients with multiple myeloma (MM), 166 patients receiving autologous
transplantation (124 PBSC and 38 BM) and 66 patients receiving T-cell-depleted allogeneic …

We previously reported initial results in 102 multiple myeloma (MM) patients treated with
sequential high-dose melphalan and autologous hematopoietic cell transplantation followed …

Simple Summary Patients with multiple myeloma (MM) refractory to conventional treatment
strategies represent an unmet medical need. Allogeneic stem cell transplantation (allo …

We conducted a study of patients with multiple myeloma (MM) undergoing allogeneic
transplantation to evaluate outcome parameters. Fifty-seven consecutive patients with MM …

Although generally not applied as first-line treatment of multiple myeloma, allogeneic
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …

Background Allogeneic transplant in myeloma remains controversial. Patients and Methods
We performed a retrospective review of 76 patients in the Mayo Clinic database from 1993 to …

Allogeneic stem cell transplantation (allo-SCT) using reduced-intensity conditioning (RIC) is
a feasible procedure in selected patients with relapsed multiple myeloma (MM), but its …

We performed a retrospective analysis of outcome in 45 patients with multiple myeloma
receiving unrelated donor stem cell transplants (UD‐SCT) in the UK between 1993 and …